Table 2:
Estimated lifetime number of diagnosed cases of disease attributable to HPV infections acquired in 2018
| Health outcome | Mean (10th–90th percentiles) result from HPV-ADVISE model |
|
|---|---|---|
| Ages 15–59 years | Ages 15–24 years | |
| Genital warts | ||
| Females | 25,442 (15,621–35,484) | 6,310 (4,632–8,531) |
| Males | 24,967 (16,721–33,128) | 2,325 (3,217–1,555) |
| Total | 50,409 (32,343–68,612) | 8,635 (7,849–10,087) |
| CIN grade 1 | 162,974 (11,572–393,451) | 103,660 (6,953–275,583) |
| CIN grade 2 or 3 | 52,074 (33,752–66,540) | 29,707 (18,751–40,031) |
| Penile cancer | 454 (279–838) | 265 (169–474) |
| Cervical cancer | 3,153 (1,912–4,674) | 1,978 (1,307–2,782) |
| Vulvar & vaginal cancer | 849 (559–1,300) | 550 (381–751) |
| Anal cancer | ||
| Females | 780 (524–1,218) | 441 (320–593) |
| Males | 675 (402–1,271) | 268 (174–491) |
| Total | 1,456 (925–2,489) | 708 (494–1,084) |
| Oropharyngeal cancer | ||
| Females | 587 (388–904) | 370 (260–505) |
| Males | 3,665 (2,233–6,868) | 1,462 (964–2,655) |
| Total | 4,252 (2,621–7,772) | 1,832 (1,225–3,160) |
Case numbers were calculated for females and males using rates of health outcomes per 100,000 from the HPV-ADVISE model multiplied by 2018 population estimates from the 2018 American Community Survey 1-Year Estimates, Table S0201,using American FactFinder; http://factfinder.census.gov. Total case numbers were calculated as the sum of case numbers in females and males. The age groupings refer to age at the time of the causal HPV infection (2018), not the age at which the health outcome was diagnosed.